NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
- PMID: 22852078
- PMCID: PMC3407651
- DOI: 10.1155/2012/123253
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
Abstract
Anaplastic lymphoma kinase (ALK) was first identified in 1994 with the discovery that the gene encoding for this kinase was involved in the t(2;5)(p23;q35) chromosomal translocation observed in a subset of anaplastic large cell lymphoma (ALCL). The NPM-ALK fusion protein generated by this translocation is a constitutively active tyrosine kinase, and much research has focused on characterizing the signalling pathways and cellular activities this oncoprotein regulates in ALCL. We now know about the existence of nearly 20 distinct ALK translocation partners, and the fusion proteins resulting from these translocations play a critical role in the pathogenesis of a variety of cancers including subsets of large B-cell lymphomas, nonsmall cell lung carcinomas, and inflammatory myofibroblastic tumours. Moreover, the inhibition of ALK has been shown to be an effective treatment strategy in some of these malignancies. In this paper we will highlight malignancies where ALK translocations have been identified and discuss why ALK fusion proteins are constitutively active tyrosine kinases. Finally, using ALCL as an example, we will examine three key signalling pathways activated by NPM-ALK that contribute to proliferation and survival in ALCL.
Figures



Similar articles
-
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.Leukemia. 2000 Sep;14(9):1533-59. doi: 10.1038/sj.leu.2401878. Leukemia. 2000. PMID: 10994999 Review.
-
The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.BMC Cancer. 2012 Jun 8;12:229. doi: 10.1186/1471-2407-12-229. BMC Cancer. 2012. PMID: 22681779 Free PMC article.
-
Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.Blood. 1995 Sep 15;86(6):2321-8. Blood. 1995. PMID: 7662979
-
Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.Leuk Res. 2008 Mar;32(3):383-93. doi: 10.1016/j.leukres.2007.07.012. Epub 2007 Aug 27. Leuk Res. 2008. PMID: 17720243
-
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22. Blood. 2017. PMID: 27879258 Review.
Cited by
-
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.Cancer Res. 2015 Jul 15;75(14):2916-27. doi: 10.1158/0008-5472.CAN-14-3437. Epub 2015 May 27. Cancer Res. 2015. PMID: 26018086 Free PMC article.
-
PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.Biomedicines. 2022 Jul 4;10(7):1587. doi: 10.3390/biomedicines10071587. Biomedicines. 2022. PMID: 35884893 Free PMC article. Review.
-
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.ISRN Hematol. 2013;2013:348212. doi: 10.1155/2013/348212. Epub 2013 Jan 29. ISRN Hematol. 2013. PMID: 23431463 Free PMC article.
-
Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.J Cheminform. 2017 Jul 4;9(1):43. doi: 10.1186/s13321-017-0229-8. J Cheminform. 2017. PMID: 29086093 Free PMC article.
-
Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma.Front Oncol. 2020 May 8;10:730. doi: 10.3389/fonc.2020.00730. eCollection 2020. Front Oncol. 2020. PMID: 32457846 Free PMC article.
References
-
- Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89(4):1394–1404. - PubMed
-
- Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439–449. - PubMed
-
- Morris SW, Naeve C, Mathew P, et al. ALK the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene. 1997;14(18):2175–2188. - PubMed
-
- Vernersson E, Khoo NKS, Henriksson ML, Roos G, Palmer RH, Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expression Patterns. 2006;6(5):448–461. - PubMed
LinkOut - more resources
Full Text Sources